260 related articles for article (PubMed ID: 26599461)
1. Disulfiram and its novel derivative sensitize prostate cancer cells to the growth regulatory mechanisms of the cell by re-expressing the epigenetically repressed tumor suppressor-estrogen receptor β.
Sharma V; Verma V; Lal N; Yadav SK; Sarkar S; Mandalapu D; Porwal K; Rawat T; Maikhuri JP; Rajender S; Sharma VL; Gupta G
Mol Carcinog; 2016 Nov; 55(11):1843-1857. PubMed ID: 26599461
[TBL] [Abstract][Full Text] [Related]
2. Disulfiram is a DNA demethylating agent and inhibits prostate cancer cell growth.
Lin J; Haffner MC; Zhang Y; Lee BH; Brennen WN; Britton J; Kachhap SK; Shim JS; Liu JO; Nelson WG; Yegnasubramanian S; Carducci MA
Prostate; 2011 Mar; 71(4):333-43. PubMed ID: 20809552
[TBL] [Abstract][Full Text] [Related]
3. Sensitization of androgen refractory prostate cancer cells to anti-androgens through re-expression of epigenetically repressed androgen receptor - Synergistic action of quercetin and curcumin.
Sharma V; Kumar L; Mohanty SK; Maikhuri JP; Rajender S; Gupta G
Mol Cell Endocrinol; 2016 Aug; 431():12-23. PubMed ID: 27132804
[TBL] [Abstract][Full Text] [Related]
4. DNA demethylation and histone deacetylation inhibition co-operate to re-express estrogen receptor beta and induce apoptosis in prostate cancer cell-lines.
Walton TJ; Li G; Seth R; McArdle SE; Bishop MC; Rees RC
Prostate; 2008 Feb; 68(2):210-22. PubMed ID: 18092350
[TBL] [Abstract][Full Text] [Related]
5. Epigenetic reactivation of RASSF1A by phenethyl isothiocyanate (PEITC) and promotion of apoptosis in LNCaP cells.
Boyanapalli SS; Li W; Fuentes F; Guo Y; Ramirez CN; Gonzalez XP; Pung D; Kong AN
Pharmacol Res; 2016 Dec; 114():175-184. PubMed ID: 27818231
[TBL] [Abstract][Full Text] [Related]
6. Promoter CpG-Site Methylation of the KAI1 Metastasis Suppressor Gene Contributes to Its Epigenetic Repression in Prostate Cancer.
Lee J; Lee MS; Jeoung DI; Kim YM; Lee H
Prostate; 2017 Mar; 77(4):350-360. PubMed ID: 27813113
[TBL] [Abstract][Full Text] [Related]
7. Correlation between the germline methylation status in ERβ promoter and the risk in prostate cancer: a prospective study.
Wang L; Zhang P; Meng X; Chen X; Xiang Z; Lin X; Liu Y; Gan W; Han X; Li D
Fam Cancer; 2016 Apr; 15(2):309-15. PubMed ID: 26547439
[TBL] [Abstract][Full Text] [Related]
8. Identification of a novel quinoline-based DNA demethylating compound highly potent in cancer cells.
Zwergel C; Schnekenburger M; Sarno F; Battistelli C; Manara MC; Stazi G; Mazzone R; Fioravanti R; Gros C; Ausseil F; Florean C; Nebbioso A; Strippoli R; Ushijima T; Scotlandi K; Tripodi M; Arimondo PB; Altucci L; Diederich M; Mai A; Valente S
Clin Epigenetics; 2019 May; 11(1):68. PubMed ID: 31060628
[TBL] [Abstract][Full Text] [Related]
9. Anti-tumoral effect of the non-nucleoside DNMT inhibitor RG108 in human prostate cancer cells.
Graça I; Sousa EJ; Baptista T; Almeida M; Ramalho-Carvalho J; Palmeira C; Henrique R; Jerónimo C
Curr Pharm Des; 2014; 20(11):1803-11. PubMed ID: 23888969
[TBL] [Abstract][Full Text] [Related]
10. Reversal of GSTP1 CpG island hypermethylation and reactivation of pi-class glutathione S-transferase (GSTP1) expression in human prostate cancer cells by treatment with procainamide.
Lin X; Asgari K; Putzi MJ; Gage WR; Yu X; Cornblatt BS; Kumar A; Piantadosi S; DeWeese TL; De Marzo AM; Nelson WG
Cancer Res; 2001 Dec; 61(24):8611-6. PubMed ID: 11751372
[TBL] [Abstract][Full Text] [Related]
11. Benzopyran derivative CDRI-85/287 induces G2-M arrest in estrogen receptor-positive breast cancer cells via modulation of estrogen receptors α- and β-mediated signaling, in parallel to EGFR signaling and suppresses the growth of tumor xenograft.
Saxena R; Fatima I; Chandra V; Blesson CS; Kharkwal G; Hussain MK; Hajela K; Roy BG; Dwivedi A
Steroids; 2013 Nov; 78(11):1071-86. PubMed ID: 23891847
[TBL] [Abstract][Full Text] [Related]
12. Expression of estrogen receptor (ER)-alpha and ER-beta in normal and malignant prostatic epithelial cells: regulation by methylation and involvement in growth regulation.
Lau KM; LaSpina M; Long J; Ho SM
Cancer Res; 2000 Jun; 60(12):3175-82. PubMed ID: 10866308
[TBL] [Abstract][Full Text] [Related]
13. Genistein increases estrogen receptor beta expression in prostate cancer via reducing its promoter methylation.
Mahmoud AM; Al-Alem U; Ali MM; Bosland MC
J Steroid Biochem Mol Biol; 2015 Aug; 152():62-75. PubMed ID: 25931004
[TBL] [Abstract][Full Text] [Related]
14. Nc886 is epigenetically repressed in prostate cancer and acts as a tumor suppressor through the inhibition of cell growth.
Fort RS; Mathó C; Geraldo MV; Ottati MC; Yamashita AS; Saito KC; Leite KRM; Méndez M; Maedo N; Méndez L; Garat B; Kimura ET; Sotelo-Silveira JR; Duhagon MA
BMC Cancer; 2018 Feb; 18(1):127. PubMed ID: 29394925
[TBL] [Abstract][Full Text] [Related]
15. High-throughput cell-based screening of 4910 known drugs and drug-like small molecules identifies disulfiram as an inhibitor of prostate cancer cell growth.
Iljin K; Ketola K; Vainio P; Halonen P; Kohonen P; Fey V; Grafström RC; Perälä M; Kallioniemi O
Clin Cancer Res; 2009 Oct; 15(19):6070-8. PubMed ID: 19789329
[TBL] [Abstract][Full Text] [Related]
16. Estrogen regulates tumor growth through a nonclassical pathway that includes the transcription factors ERβ and KLF5.
Nakajima Y; Akaogi K; Suzuki T; Osakabe A; Yamaguchi C; Sunahara N; Ishida J; Kako K; Ogawa S; Fujimura T; Homma Y; Fukamizu A; Murayama A; Kimura K; Inoue S; Yanagisawa J
Sci Signal; 2011 Apr; 4(168):ra22. PubMed ID: 21487105
[TBL] [Abstract][Full Text] [Related]
17. Promoter hypermethylation as a novel regulator of ANO1 expression and function in prostate cancer bone metastasis.
Shin Y; Kim S; An W
Sci Rep; 2024 May; 14(1):11595. PubMed ID: 38773164
[TBL] [Abstract][Full Text] [Related]
18. PC3, but not DU145, human prostate cancer cells retain the coregulators required for tumor suppressor ability of androgen receptor.
Litvinov IV; Antony L; Dalrymple SL; Becker R; Cheng L; Isaacs JT
Prostate; 2006 Sep; 66(12):1329-38. PubMed ID: 16835890
[TBL] [Abstract][Full Text] [Related]
19. DNMT1 and DNMT3B regulate tumorigenicity of human prostate cancer cells by controlling RAD9 expression through targeted methylation.
Zhu A; Hopkins KM; Friedman RA; Bernstock JD; Broustas CG; Lieberman HB
Carcinogenesis; 2021 Feb; 42(2):220-231. PubMed ID: 32780107
[TBL] [Abstract][Full Text] [Related]
20. CpG island promoter methylation and silencing of 14-3-3sigma gene expression in LNCaP and Tramp-C1 prostate cancer cell lines is associated with methyl-CpG-binding protein MBD2.
Pulukuri SM; Rao JS
Oncogene; 2006 Aug; 25(33):4559-72. PubMed ID: 16786000
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
